Meglumine Antimoniate
Mostrando 1-12 de 52 artigos, teses e dissertações.
-
1. Multivariate Optimization Applied to the Synthesis of Meglumine Antimoniate with Low Levels of Trivalent Antimony
Meglumine antimoniate (MA) is a pentavalent antimony (SbV) drug recommended for the treatment of leishmaniasis. It is known that the trivalent antimony (SbIII) present as a residue in MA contributes to the drug side effects. In this article, multivariate optimization was used in the synthesis of MA in order to obtain a drug with low levels of SbIII. Four var
J. Braz. Chem. Soc.. Publicado em: 2021-08
-
2. Speciation of Antimony in Injectable Leishmanicidal Drugs by Lowering Citric Acid Concentration Used in Hydride Generation Atomic Absorption Spectrometry Analysis
This study proposes a procedure for speciation of antimony by hydride generation atomic absorption spectrometry in pentavalent antimony drugs. The SbIII content was determined by selective generation of SbH3 in medium with higher SbV concentration using 4 to 20-fold lower citric acid solutions than recommended in the available literature. The multivariate op
J. Braz. Chem. Soc.. Publicado em: 2021-01
-
3. Oncologia Ocular no Brasil: Qual o nosso passado, presente e futuro?
This study proposes a procedure for speciation of antimony by hydride generation atomic absorption spectrometry in pentavalent antimony drugs. The SbIII content was determined by selective generation of SbH3 in medium with higher SbV concentration using 4 to 20-fold lower citric acid solutions than recommended in the available literature. The multivariate op
Arq. Bras. Oftalmol.. Publicado em: 2021-01
-
4. American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
Abstract: Pentavalent antimonials are the first-line drug treatment for American tegumentary leishmaniasis. We report on a patient with chronic renal failure on hemodialysis who presented with cutaneous lesions of leishmaniasis for four months. The patient was treated with intravenous meglumine under strict nephrological surveillance, but cardiotoxicity, acu
An. Bras. Dermatol.. Publicado em: 29/07/2019
-
5. Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
Abstract Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine antimoniate administration has fewer adverse effects and can be as effective and safe. We describe 12 patients treated with intralesional meglumine antimoniate: seven with primary a
Rev. Soc. Bras. Med. Trop.. Publicado em: 16/05/2019
-
6. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis
Abstract INTRODUCTION: The treatment of mucosal leishmaniasis (ML) is difficult due to the toxicity and route of administration of standard drugs. Miltefosine is an oral agent used for leishmaniasis treatment; however, no data exist regarding its use for ML in Brazil. In this study, we aimed to evaluate the efficacy of miltefosine for ML treatment compared
Rev. Soc. Bras. Med. Trop.. Publicado em: 28/03/2019
-
7. Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice
Abstract Background: Cutaneous leishmaniasis (CL) is a parasitic disease caused by the protozoan Leishmania spp. Pentavalent antimonial agents have been used as an effective therapy, despite their side effects and resistant cases. Their pharmacokinetics remain largely unexplored. This study aimed to investigate the pharmacokinetic profile of meglumine anti
J. Venom. Anim. Toxins incl. Trop. Dis. Publicado em: 11/03/2019
-
8. Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report
Abstract In Brazil, meglumine antimoniate is the first drug of choice for mucosal leishmaniasis treatment followed by amphotericin B and pentamidine isethionate. We report the case of a patient with severe mucosal lesions caused by Leishmania (Viannia) braziliensis that were difficult to treat. Over a 14-year period, the patient showed low adherence and thre
Rev. Soc. Bras. Med. Trop.. Publicado em: 17/01/2019
-
9. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
BACKGROUND Cutaneous leishmaniasis (CL) is a world-wide health problem which currently lacks effective, affordable and easy to use therapy. Recently, the meglumine antimoniate (MA) intralesional infiltration was included among the acceptable therapies for New World leishmaniasis. While this approach is attractive, there is currently little evidence to supp
Mem. Inst. Oswaldo Cruz. Publicado em: 21/06/2018
-
10. Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment
BACKGROUND Despite its recognised toxicity, antimonial therapy continues to be the first-line drug for cutaneous leishmaniasis (CL) treatment. Intralesional administration of meglumine antimoniate (MA) represents an alternative that could reduce the systemic absorption of the drug and its side effects. OBJECTIVES This study aims to validate the standard op
Mem. Inst. Oswaldo Cruz. Publicado em: 2018-02
-
11. Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)
BACKGROUND American tegumentary leishmaniasis (ATL) is a non-lethal parasitic disease that presents with cutaneous (CL) and mucosal (ML) clinical forms. ATL treatment aims at healing the lesions and preventing the development of the late mucosal form. Systemic meglumine antimoniate (MA) therapy with 10-20 mg Sb5+/kg/day is the first choice of treatment. How
Mem. Inst. Oswaldo Cruz. Publicado em: 2017-12
-
12. Disseminated cutaneous leishmaniasis caused by Leishmania braziliensis in Southern Brazil
ABSTRACT The authors report a case of disseminated cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis, in a 55 years old patient with 1,119 lesions distributed throughout the body. The patient resides in Sabáudia municipality, North of Paraná State, Southern Brazil, where there was no previous report of this form of leishmaniasis. Treatmen
Rev. Inst. Med. trop. S. Paulo. Publicado em: 01/06/2017